Bionime Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Bionime.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth	22.5%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?

Mar 23

Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?

Mar 05

Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?

Feb 15

Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet

Feb 01

How Has Bionime (TPE:4737) Allocated Its Capital?

Jan 19

A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE

Jan 06

A Look At The Fair Value Of Bionime Corporation (TPE:4737)

Dec 22

Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend

Dec 09

Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment

Nov 24

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bionime has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TWSE:4737 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	1,921	-83	-121	185	N/A
6/30/2024	1,858	-40	-308	101	N/A
3/31/2024	1,809	7	-305	95	N/A
12/31/2023	1,756	6	-238	203	N/A
9/30/2023	1,863	22	-163	297	N/A
6/30/2023	2,002	43	-109	284	N/A
3/31/2023	2,150	72	26	393	N/A
12/31/2022	2,211	91	-171	142	N/A
9/30/2022	2,091	95	-189	91	N/A
6/30/2022	2,023	115	-139	129	N/A
3/31/2022	1,862	89	-208	84	N/A
12/31/2021	1,850	87	-15	270	N/A
9/30/2021	1,879	101	2	254	N/A
6/30/2021	1,832	111	-58	205	N/A
3/31/2021	1,779	83	-62	204	N/A
12/31/2020	1,669	62	-79	218	N/A
9/30/2020	1,913	73	-20	270	N/A
6/30/2020	1,951	38	-4	247	N/A
3/31/2020	2,162	91	248	456	N/A
12/31/2019	2,173	106	267	406	N/A
9/30/2019	2,043	112	117	243	N/A
6/30/2019	2,113	132	55	208	N/A
3/31/2019	1,986	121	-98	64	N/A
12/31/2018	2,007	128	-47	122	N/A
9/30/2018	1,962	114	2	164	N/A
6/30/2018	1,842	135	N/A	166	N/A
3/31/2018	1,821	137	N/A	99	N/A
12/31/2017	1,820	150	N/A	30	N/A
9/30/2017	1,771	174	N/A	134	N/A
6/30/2017	1,780	181	N/A	275	N/A
3/31/2017	1,791	192	N/A	420	N/A
12/31/2016	1,740	179	N/A	458	N/A
9/30/2016	1,654	143	N/A	441	N/A
6/30/2016	1,637	119	N/A	373	N/A
3/31/2016	1,571	91	N/A	228	N/A
12/31/2015	1,610	99	N/A	200	N/A
9/30/2015	1,634	101	N/A	271	N/A
6/30/2015	1,591	82	N/A	305	N/A
3/31/2015	1,571	72	N/A	354	N/A
12/31/2014	1,525	54	N/A	360	N/A
9/30/2014	1,446	22	N/A	272	N/A
6/30/2014	1,459	43	N/A	148	N/A
3/31/2014	1,536	72	N/A	165	N/A
12/31/2013	1,561	90	N/A	129	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 4737's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 4737's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 4737's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 4737's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 4737's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4737's Return on Equity is forecast to be high in 3 years time

Bionime Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased to NT$85.00

Recent updates

Third quarter 2024 earnings released: NT$0.88 loss per share (vs NT$0.17 loss in 3Q 2023)

Bionime Corporation to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Bionime Corporation to Report Q2, 2024 Results on Aug 08, 2024

Bionime (TWSE:4737) Is Reducing Its Dividend To NT$2

Upcoming dividend of NT$2.00 per share

Bionime (TWSE:4737) Will Pay A Smaller Dividend Than Last Year

Dividend reduced to NT$2.00

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Bionime Corporation to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings released: EPS: NT$0.10 (vs NT$1.50 in FY 2022)

Bionime Corporation, Annual General Meeting, Jun 28, 2024

New minor risk - Earnings quality

Bionime Corporation Announces TFDA Approval for iFree Continuous Glucose Monitoring System Second-Class Medical Device License

Bionime Corporation Announces Resignation of Marvin Wu as Globle Sales Division Officer

Second quarter 2023 earnings released: EPS: NT$0.17 (vs NT$0.65 in 2Q 2022)

Bionime Corporation Announces Appointment of Aling Lai as New Member to the Remuneration Committee

Upcoming dividend of NT$2.10 per share at 2.7% yield

Bionime Corporation Appoints Aling Lai as Additional Member of Audit Committee

Full year 2022 earnings: EPS misses analyst expectations

Price target increased to NT$85.00

Less than half of directors are independent

Third quarter 2022 earnings: EPS misses analyst expectations

Bionime Corporation Got A Taiwan Clinical Study Report for Continuous Glucose Monitoring System

Second quarter 2022 earnings released: EPS: NT$0.65 (vs NT$0.22 in 2Q 2021)

Less than half of directors are independent

Upcoming dividend of NT$2.00 per share

Bionime Corporation Announces Members of the First Order Audit Committee of the Company

Less than half of directors are independent

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Bionime Corporation Announces Replacement of the Representative of the Its Institutional Director

Third quarter 2021 earnings released: EPS NT$0.51 (vs NT$0.68 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.22 (vs NT$0.26 loss in 2Q 2020)

Upcoming dividend of NT$2.06 per share

First quarter 2021 earnings released: EPS NT$0.20 (vs NT$0.14 loss in 1Q 2020)

These Return Metrics Don't Make Bionime (TPE:4737) Look Too Strong

Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?

Full year 2020 earnings released: EPS NT$1.06 (vs NT$1.85 in FY 2019)

Bionime Corporation Announces Dividend for the Year 2020

Bionime Corporation, Annual General Meeting, Jun 24, 2021

Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?

Investor sentiment improved over the past week

Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?

New 90-day low: NT$62.30

Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet

Bionime Corporation Announces Change to the Principal Accounting Officer of the Company

New 90-day low: NT$64.50

How Has Bionime (TPE:4737) Allocated Its Capital?

A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE

A Look At The Fair Value Of Bionime Corporation (TPE:4737)

Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend

New 90-day low: NT$68.20

Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment

Third quarter 2020 earnings released: EPS NT$0.68

First half earnings released

Upcoming Dividend of NT$1.99 Per Share

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies